Still, recent improvements in neoadjuvant regimens, such as the implementation of endocrine therapy in strongly ER-positive, luminal breast cancers, pertuzumab for HER2-positive tumors, and platinum and immune checkpoint inhibitors for TNBC, would be considered more preferable if a similar trial was designed today. Here, ERBB2 is linked to breast cancer.